Latest Uk Hospitals News

Alcidion will roll out its Miya Flow software across four Northern Care Alliance hospitals under a new A$7.5 million contract. About A$4.5 million is expected to be recognised as revenue in the current year, including a six-month renewal of the existing ExtraMed system during implementation.

Ramsay Health Care delivered stronger FY26 earnings, a higher fully franked dividend and improved Funding Group leverage as it prepares to separate Ramsay Santé. The proposed demerger remains conditional, but the company has set a clear timetable for the next phase of its portfolio reshaping.

Alcidion has landed a $35 million, seven-year contract to deploy its Miya Precision Electronic Patient Record platform at University Hospitals Sussex, marking a significant expansion in the UK healthcare IT market.

Alcidion Group has been named preferred supplier for a major UK hospital's Electronic Patient Record system, driving a 40% jump in contracted revenue and a robust cash position in Q2 FY26.

Nexsen Limited has appointed internationally acclaimed surgeon-scientist Professor Shekhar Kumta to its board, aiming to fast-track clinical validation and regulatory approval for its rapid diagnostic platforms ahead of a planned 2026 market entry.

Ramsay Health Care reported a modest 1.7% increase in underlying net profit for FY25, driven by strong Australian and UK hospital performances despite significant impairments in the UK. The company is advancing its multi-year transformation and expects EBIT growth in Australia for FY26, though challenges remain.

Ramsay Health Care posted solid revenue growth driven by its Australian and UK hospital businesses, despite a significant impairment charge impacting net profit. The group advances a multi-year transformation focusing on operational efficiency and capital discipline.

Ramsay Health Care has announced a significant $305 million impairment in its UK segment driven by challenges at Elysium, alongside a $64.5 million tax provision release linked to Ramsay Santé. The company is taking decisive steps to address operational weaknesses while its core UK hospitals show promising growth.

Genetic Signatures reported a robust 190% increase in quarterly sales to $3.8 million, driven by strong respiratory testing demand in Australia and strategic UK deployments. Despite longer US sales cycles, the company maintains a solid $40.8 million cash position and advances R&D on its 3base® platform.